How much did biotechnology R&D obligate in FY2024?

USAspending.gov records $17,850,721,064.74 in Research And Development In Biotechnology obligations for FY2024 under NAICS 541711. That yearlyTrend total is not an outlay and not the industry's $18,258,755,045.17 extract-wide sum. Keep Research And Development In Biotechnology and FY2024 on the same citation as $17,850,721,064.74.

Is this the same as NAICS 541714 biotechnology R&D?

No. This join is 541711. 541714 is Research And Development In Biotechnology (Except Nanobiotechnology), a different code with its own FY2024 cell. FY2024 is 97.8% of 541711's $18,258,755,045.17 extract-wide total. 473 is the industry extract award-record count, not a FY2024 headcount.

Are 473 awards the FY2024 biotech grant count?

No. 473 is the 541711 extract award-record count, not a FY2024-only tally. The packet does not name labs. Obligations of $17,850,721,064.74 are not outlays. The pair is NAICS 541711 plus FY2024. The pair is NAICS 541711 plus FY2024.

Does this page report trial funding already paid?

No. $17,850,721,064.74 is an obligation aggregate. Outlays, campus shares, and investigator names are unpublished. FEC donations are a different dataset and do not fund this total. USAspending.gov remains the source for NAICS 541711 in FY2024.

← All data ties

Research And Development In Biotechnology federal obligations in FY2024

$17,850,721,064.74 is the USAspending.gov obligation sum for Research And Development In Biotechnology in fiscal year 2024. Under NAICS 541711, that yearlyTrend cell is 97.8% of the industry's $18,258,755,045.17 extract-wide total — almost the entire published series sits in this year. The pair is biotechnology R&D plus FY2024, not a trial census and not cash already paid. The extract publishes 473 541711 award records industry-wide, a compact file that is not a FY2024-only grant list.

Key figures

USAspending records $17,850,721,064.74 in Research And Development In Biotechnology FY2024 obligations (NAICS 541711).
FY2024 is 97.8% of the industry's $18,258,755,045.17 extract-wide total.
NAICS 541714 is a different biotechnology R&D code, not this cell.
473 is an industry-extract award-record count, not a FY2024 grant census.

541711 dollars tagged to FY2024

NAICS 541711 and fiscal year 2024 form one pair. $17,850,721,064.74 is the obligation sum USAspending.gov attaches to that pair. It is not Research And Development In Biotechnology (Except Nanobiotechnology) coded 541714, not the $18,258,755,045.17 all-year 541711 book as a second addend, and not an outlay. 541714 has its own FY2024 cell on this slice. The packet does not name labs or principal investigators.

A near-complete year-share can look like a closed R&D program. Other years still exist as other rows even when 97.8% is high. Ranking campuses from this total would invent a table. Correlation with trial headlines is not causation.

FY2024 versus 541711's extract-wide total

97.8% of $18,258,755,045.17 sits on the FY2024 yearlyTrend row. The Research And Development In Biotechnology hub (/industries/541711/) drops the year filter. FY2024 federal spending (/fiscal-years/2024/) drops the 541711 filter. Neither parent equals $17,850,721,064.74.

Do not add 541714's FY2024 cell into this 541711 total. Different NAICS strings are different joins even when both mention biotechnology. Cite $17,850,721,064.74 as obligations, not as grants already drawn by a named campus.

How to read 541711's 473 award records

473 is a compact industry-extract action count. It is not the number of FY2024 grants, not a count of trials, and not a count of investigators. Mixing $17,850,721,064.74 with 473 as a mean FY2024 award would blend a one-year dollar field with a multi-year row field. This page does not publish that blend.

What the 541711–FY2024 packet leaves out

No outlays, no agency pie, no named universities, no state table. Campaign-finance filings do not fund these USAspending obligations. Quote NAICS 541711, FY2024, and $17,850,721,064.74 together. All industries (/industries/) and All spending ties (/ties/) list other keys that must stay outside this cell.

Citing biotechnology R&D in FY2024

Use /industries/541711/ for the 541711 hub, /fiscal-years/2024/ for the FY2024 government-wide hub, /industries/ for the industry index, and /ties/ for other pairs. Keep Research And Development In Biotechnology and FY2024 on the same line as $17,850,721,064.74.

The 473 award-record figure stays attached to NAICS 541711's extract, not to this yearlyTrend row. Original award filings remain on USAspending.gov. Obligations of $17,850,721,064.74 are not outlays. Keep Research And Development In Biotechnology and FY2024 together when citing $17,850,721,064.74. NAICS 541711's extract-wide award-record count is 473, not a FY2024 census. Obligations of $17,850,721,064.74 are not outlays. Original filings remain on USAspending.gov for this 541711 × FY2024 pair. Do not add parent hubs into this yearlyTrend cell. Campaign-finance tables do not fund these USAspending obligations. The 97.8% share is $17,850,721,064.74 divided by the extract-wide $18,258,755,045.17, not a budget score. Unique recipients remain unpublished on this Research And Development In Biotechnology FY2024 join. Agency and place-of-performance splits are omitted from this packet. Quote NAICS 541711, fiscal year 2024, and $17,850,721,064.74 in one sentence. The All industries index and All spending ties index are larger than this cell. A later USAspending ingest can restate $17,850,721,064.74 without changing the join keys. Keep Research And Development In Biotechnology and FY2024 together when citing $17,850,721,064.74. NAICS 541711's extract-wide award-record count is 473, not a FY2024 census. Obligations of $17,850,721,064.74 are not outlays. Original filings remain on USAspending.gov for this 541711 × FY2024 pair. Do not add parent hubs into this yearlyTrend cell. Campaign-finance tables do not fund these USAspending obligations. The 97.8% share is $17,850,721,064.74 divided by the extract-wide $18,258,755,045.17, not a budget score.

Questions

How much did biotechnology R&D obligate in FY2024?: USAspending.gov records $17,850,721,064.74 in Research And Development In Biotechnology obligations for FY2024 under NAICS 541711. That yearlyTrend total is not an outlay and not the industry's $18,258,755,045.17 extract-wide sum. Keep Research And Development In Biotechnology and FY2024 on the same citation as $17,850,721,064.74.
Is this the same as NAICS 541714 biotechnology R&D?: No. This join is 541711. 541714 is Research And Development In Biotechnology (Except Nanobiotechnology), a different code with its own FY2024 cell. FY2024 is 97.8% of 541711's $18,258,755,045.17 extract-wide total. 473 is the industry extract award-record count, not a FY2024 headcount.
Are 473 awards the FY2024 biotech grant count?: No. 473 is the 541711 extract award-record count, not a FY2024-only tally. The packet does not name labs. Obligations of $17,850,721,064.74 are not outlays. The pair is NAICS 541711 plus FY2024. The pair is NAICS 541711 plus FY2024.
Does this page report trial funding already paid?: No. $17,850,721,064.74 is an obligation aggregate. Outlays, campus shares, and investigator names are unpublished. FEC donations are a different dataset and do not fund this total. USAspending.gov remains the source for NAICS 541711 in FY2024.

USAspending.gov NAICS yearlyTrend by fiscal year. Obligations are not outlays. FY figures can be incomplete for the current year.